Objective: C-reactive protein (CRP) is an inflammatory marker that contributes to the prediction of cardiovascular diseases (CVD). We investigated the influences of CRP polymorphisms on baseline CRP levels and fenofibrate-induced CRP changes in subjects with the metabolic syndrome (MetS).
-reactive protein (CRP) is an important downstream inflammatory marker that integrates the action of several activated cytokines. Current evidence suggests that plasma CRP levels may be an independent predictor of clinical cardiovascular events in both healthy individuals and cardiovascular diseases (CVD) patients (1) . In addition, elevated CRP has been shown to associate with multiple risk factors for CVD including obesity, insulin resistance and hypertension, and to predict risk of metabolic syndrome (MetS) and diabetes (2) .
Plasma CRP levels display extensive inter-individual variability. While plasma CRP levels are influenced by a number of factors including sociodemographic, behavioral and lifestyle factors, obesity and type 2 diabetes, twin and family studies have estimated that genetic factors could contribute up to 35%-50% of the variation of CRP (3; 4) . Several population-based association studies have shown that common genetic variants at the CRP locus are significantly associated with plasma CRP levels (3) (4) (5) . Furthermore, the CRP locus has been shown to associate with CVD risk (4), providing additional support for a causal role of CRP in CVD. In line with these results, in vitro studies reveal that the CRP upstream region harbors functional polymorphisms which potentially alter binding affinities of different transcription factors and thus affect transcription of the CRP gene (3) . In addition to baseline CRP levels, CRP SNPs also contribute to variation of inflammatory responses to certain stimuli. The T allele of SNP1444C>T (rs 1130864) has been reported to affect both baseline CRP and inflammatory responses to experimental lipopolysaccharide (LPS)-induced endotoxemia in healthy adults (6) . This allele is also associated with differential CRP responses in patients undergoing periodontal treatment and coronary artery bypass graft surgery (5; 7). These findings prompted us to examine the effects of genetic variants of CRP gene on the response of CRP to fenofibrate which, in addition to their lipid-lowering action, have anti-inflammatory activity (8) .
Fenofibrate is a drug of the fibrate class commonly used for the management of dyslipidemia. A growing body of evidence has suggested that fibrates target both the atherogenic "lipid triad" (high triglycerides and low HDL with small and dense LDL particles) and inflammation (8) . Because both phenotypes are important components of diabetes and the MetS and potentially link these two metabolic disorders to CVD (9) , fibrates appear to be well suited for treating dyslipidemia associated with diabetes and the MetS and more effective to reduce CVD in those high-risk populations (10) . However, individual's response to fenofibrate is highly variable. Prior studies have reported that genetic variants at genes involved in lipid metabolism modulate lipid response to fenofibrate (11) . However, the effect of CRP variants on the anti-inflammatory effect of fenofibrate may be a significant determinant of its therapeutic success and it remains to be investigated.
Therefore, the goals of our study were 1) to examine the effect of common CRP polymorphisms on baseline plasma CRP levels among US white participants in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study and 2) to investigate the effect of these variants on the response of CRP to a 3-week fenofibrate treatment in GOLDN participant with the MetS who in the population represent the obvious target of this family of drugs.
RESEARCH DESIGN AND METHODS

Subjects.
The study population consisted of 539 men and 584 women who participated in the GOLDN study. The GOLDN study was a C single arm, uncontrolled, non-randomized intervention funded by the NHLBI with the purpose of identifying genetic variants associated with interindividual variability of triglyceride responses to a high fat meal and fenofibrate. The design and methodology of the study have been described previously (12) Biochemical Measurements. Plasma highlysensitive C-reactive protein (hsCRP) was measured using the CRP (2) K-Assay®, a latex particle enhanced immunoturbidimetric assay on the Hitachi 911 (Kamiya Biomedical Company, Seattle, WA). DNA isolation and genotyping. Genomic DNA was extracted from blood samples and purified using commercial Puregene® reagents (Gentra System, Inc.) following the manufacturer's instructions. Genotyping was performed using the 5'nuclease allelic discrimination Taqman assay with ABI 7900HT system (Applied Biosystems, Foster City, CA, USA). The description of SNPs, primer and probe sequences as well as ABI assay-on-demand IDs are presented in Supplemental Table 1 . Statistical analyses. Statistical analyses were performed using SAS version 9.0 (SAS Institute, Cary, NC). A Chi-square test was used to determine if genotype distribution followed Hardy-Weinberg equilibrium. A logarithmic transformation was applied to plasma CRP levels to normalize the distribution of data. For the additive model, the coding of the genotypes was based on the number of variant alleles at the polymorphic site. The genotypes were coded as the dummy variables in the co-dominant model. We used the generalized estimating equation (GEE) approach with exchangeable correlation structure as implemented in the GENMOD procedure in SAS to adjust for correlated observations due to familial relationships. Potential confounding factors included age, gender, BMI, smoking status, alcohol consumption, physical activity, use of aspirin, non-steroidal anti-inflammatory drugs (NSAID), drugs for lowering cholesterol, diabetes and hypertension, and hormones. Additional adjustments for baseline CRP levels, change of triglyceride and IL-6 were made for the comparison of the mean change of CRP across genotypes. Subjects with plasma CRP levels >10 mg/L at either baseline or post-treatment were excluded from the data analysis because this may indicate an ongoing acute inflammatory condition rather than low levels of chronic inflammation (13) . Pair-wise linkage disequilibrium (LD) between SNPs was estimated as a correlation coefficient (R) in unrelated subjects using the Helixtree software (Golden Helix, Inc., Bozeman, MT). Haplotypes were estimated using MERLIN (14) , which reconstructs haplotypes for a set of tightly linked markers from extended pedigrees. We used the GEE model to examine the haplotype association, in which inferred haplotypes were considered as a predictor, and the aforementioned confounding factors were considered as covariates. A two-tailed P-value of <0.05 was considered as statistically significant.
RESULTS
Baseline characteristics of the GOLDN Study population. The demographic and biochemical characteristics of subjects at baseline (mean age ± SD, 49±16y, 52% female) are presented in Table 1 . Among a total of 1123 subjects, 34% were defined as having the MetS. LD patterns among SNPs at the CRP locus. Minor allele frequencies and SNP pair-wise LD values were evaluated in a subset of 148 unrelated subjects (Supplemental Table 2 ). Genotype distributions followed HardyWeinberg equilibrium (P>0.05). SNPs m301G>A, i178T>A, 3u1273C>T and 3u2131C>T were in strong LD (r 2 =0.4-0.9, P<0.001). The m772A>G was in significant LD with the m301G>T (r 2 =0.935, P<0.001), and weak LD with the other three SNPs (r 2 =0.17, P<0.05). Because the i178T>A and the 3u1273C>T were in complete LD (r 2 = 1, P<0.001) and consequently displayed the same pattern of phenotypic associations, results for only the i178T>A SNP are presented. The association of CRP SNPs and Haplotypes with baseline CRP levels. We examined the association of total four SNPs and baseline CRP levels (Figure 1 A) . Because no significant gene-gender interactions were observed, we analyzed men and women together. All SNPs, except m772A>G, showed significant associations with plasma CRP levels in multivariate adjusted models. For m301G>A>T, major allele homozygotes exhibited the lowest CRP level, heterozygotes had an intermediate level of CRP whereas subjects with only minor alleles (T or A) had the highest CRP level (P=0.003). The minor allele of i178T>A was associated with higher CRP compared to the common allele (P=0.001). In contrast, the minor allele of 3u2131C>T was associated with lower CRP compared to the common allele (P<0.001).
The haplotype consisted of four SNPs at the CRP locus ordered from 5'to 3' along the chromosome: m772A>G, m301G>A>T, i178T>A, 3u2131C>T ("1" representing the major allele, "2" the minor allele and "3" the minor allele with the lowest frequency). Total five major haplotypes with frequency ≥ 5% were identified, representing 97% of the observed haplotypes. Baseline CRP levels significantly differed across these common haplotypes (Figure 1 B, We further examined the effects of CRP SNPs on the CRP response after a 3-week fenofibrate treatment among MetS subjects (Table 2) . Because gender did not modify genotype effects, we analyzed men and women together. Common allele homozygotes for the i178T>A displayed the highest reduction of CRP, whereas heterozygotes and minor allele homozygotes displayed an intermediate and the smallest reduction of CRP, respectively (-30% for TT, -19% for TA, -11% for AA, P for the additive model = 0.004). For m301G>A>T, genotypes were categorized into three groups based on the number of the common G allele: homozygous GG group, heterozygous GA or GT group and non-carriers group (TA or AA). The major allele carriers displayed higher reductions of CRP than non-carriers (-20% for GG, -15% for GA and GT, -0.3% for TA and AA, P for the additive model=0.02). There were no significant differences in CRP response across genotype groups for the 3u2131C>T and the m772A>G. Further haplotype analyses showed no significant effect on plasma CRP responses after the treatment (Supplemental Table 3 ). In addition, there was no significant effect of CRP genotypes on lipids, glucose and insulin responses (Supplemental Table 4 -6) .
CONCLUSIONS
In the current study, we demonstrate that common CRP polymorphisms were associated with baseline CRP levels in US White participants in the GOLDN Study. Specifically, carriers for either A or T of m301G>A>T exhibited higher CRP levels than carriers of the G allele. The minor allele of i178 T>A was associated with high CRP levels, whereas the minor allele of 3u2131C>T was associated with low CRP levels. The results were consistent with previous reports (3) (4) (5) . Furthermore, the CRP variants modulated plasma CRP response to a 3-week fenofibrate intervention among subjects with the MetS. Thus, G allele carriers for the m301G>A>T SNP displayed the greater reduction of CRP levels than noncarriers. Similarly, TT subjects for the i178T>A SNP had greater reduction in CRP levels than TA and AA subjects.
The observed association of m301G>A>T with baseline CRP levels could be due to its suggested functionality. Studies have shown that m301G>A>T resides within the hexameric core of transcription factor binding elements, and the mutations alters a transcription factor binding motif for upstream stimulating factor 1 (USF1) and thus affects the transcriptional activity of the CRP gene (3) . Because the i178 T>A is in nearly complete LD with m301G>T>A, the observed association for i178T>A simply could be attributable to this functional triallelic SNP. Interestingly, our analysis of the CRP region for transcription factor motifs using MAPPER (15) indicates that i178T>A contains a binding motif for the transcription repressor, growth factor independent 1 (GFI1), which has been shown in animal models to limit inflammatory responses (16) . Presence of the major T allele maintains the integrity of the binding site for GFI1, whereas the minor A allele abolishes this binding site. This prediction is in concordance with our observed genotypic association; thus the minor allele was associated with high CRP in a genotype dose-dependent manner. However, until further functional work substantiates these potential mechanisms, caution should be taken to interpret such a polymorphism as a functional variant. In contrast to the above two SNPs, the common allele for 3u2131C>T was associated with high CRP levels. The mechanism underlying this association could be through its LD with functional alleles, such as the triallelic SNP. Due to the moderate correlation between these two SNPs (r 2 =0.437), it is also likely that the SNP is functional as it lies in the 3'-UTR region and potentially could affect mRNA structure and stability.
We have also observed strong associations between common haplotypes and baseline CRP levels. Haplotype 1112 (m772A-m301G-i178T-3u2131T) was associated with low CRP level, whereas haplotypes 1221 (m772A-m301A-i178A-3u2131C) and 2311 (m772G-m301T-i178T-3u2131C) were associated with high CRP levels. These three haplotypes were comparable to haplotypes H3, H2 and H5 reported by Miller et al.(4) , who demonstrated that H3 associated with lower CRP, H2 and H5 with high CRP in three cohorts including the women's Health Study, the Physician's Health Study and the study of Pravastatin Inflammation/CRP Evaluation. Notably, the minor allele for m301G>A>T and the common allele for 3u2131C>T always occur on haplotypes associated with high CRP levels. This finding further supports the functional importance of these two SNPs. However, analysis of two haplotypes that only differ for 3u2131C>T showed marginally significant difference of plasma CRP levels (P=0.09), suggesting the effect of this SNP may be subject to the haplotypic context.
Studies have shown that fenofibrate along with other fibrates lowers inflammatory markers, such as CRP, in patients with dyslipidemia associated with insulin resistance, obesity and the MetS (17; 18). The anti-inflammatory action is mediated by the activation of peroxisome proliferatoractivated receptor alpha (PPARalpha), which functions as a negative regulator of genes involved in the inflammatory response by antagonizing the activity of transcription factors, such as NF-B and AP-1 (19) . However, individual response, in particular, plasma CRP response to fenofibrate is highly variable and potentially subjected to genetic regulation.
In our study, among MetS subjects major allele carriers for i178T>A (in complete LD with 3u1273C>T) had a favorable response to treatment compared to minor allele carriers. We also observed similar results for m301G>A>T, in which major allele carriers had greater CRP reduction than non-major carriers. It is of interest that the alleles associated with high baseline inflammatory status appear to be more resistant to the antiinflammatory effect of fenofibrate. Notably, under the opposite condition, such as in the presence of an inflammatory stimuli, these alleles, such as the minor allele of 3u1273C>T (previously reported as 1444C>T, rs1130864), have been shown to have a greater CRP rise (5; 7). The mechanism underlying the modulation of genetic variants on CRP response to fenofibrate is undefined. However, as both SNPs appear to be involved in transcription factor binding motifs, it is possible that the interaction of these transcription factors, in particular USF1 with PPARalpha might underlie some of the genetic effect. We postulate that the allele-specific binding of USF1 may directly interfere with PPARalphamediated transrepression of inflammatory gene expression and thus, potentially counteract PPARalpha ligand activity. It is also possible that USF1 may enhance the availability and /or DNA binding capacity of NF-KB to the CRP promoter and result in the decreased response to anti-inflammatory effect of PPARalpha. In this regard, the future in vitro studies focusing on the proteinprotein interaction and how this interaction determines the anti-inflammatory effect of fenofibrate are warranted.
We believe those findings are practically of importance for several reasons. First, although a series of large-scale intervention trials using fibrates have established the role of fibrates in normalizing lipid profiles, the results regarding their efficacy on the reduction of CVD events are inconsistent (10) . Further subgroup analyses revealed that features of the MetS modify the effect of fibrate on CVD such that cardiovascular benefits are largely confined to subjects with features of the MetS (10). Our data provide additional insight into the heterogeneity of the treatment response, suggesting that genetic difference could further differentiate individuals' response to fenofibrate, and thus potentially may affect the disease outcome among subjects at high risk. Second, if the reduction of CRP could directly lead to the decreased rate of recurrent events of CVD and the progression of coronary atherosclerosis as reported from multiple randomized clinical trials using statins (20) (-19to22 ) Values were geometric means (95%CI) adjusting for baseline CRP levels, change of triglyceride, change of IL6, age, gender, BMI, smoking status, alcohol intake, physical activity, use of aspirin and NSAID, drugs for lowering cholesterol, diabetes and hypertension, and hormone treatment in women. * Subjects with CRP>10mg/L at the baseline or after the treatment were excluded from the analysis. † Additive model.
